Abstract:Background: The ability to detect tumor-specific biomarkers in real-time using optical imaging plays a critical role in preclinical studies aimed at evaluating drug safety and treatment response. In this study, we engineered an imaging platform capable of targeting different tumor biomarkers using a multi-colored library of nanoprobes. These probes contain rare-earth elements that emit light in the short-wave infrared (SWIR) wavelength region (900-1700 nm), which exhibits reduced absorption and scattering compared to visible and NIR, and are rendered biocompatible by encapsulation in human serum albumin. The spectrally distinct emissions of the holmium (Ho), erbium (Er), and thulium (Tm) cations that constitute the cores of these nanoprobes make them attractive candidates for optical molecular imaging of multiple disease biomarkers. Methods: SWIR-emitting rare-earth-doped albumin nanocomposites (ReANCs) were synthesized using controlled coacervation, with visible light-emitting fluorophores additionally incorporated during the crosslinking phase for validation purposes. Specifically, HoANCs, ErANCs, and TmANCs were co-labeled with rhodamine-B, FITC, and Alexa Fluor 647 dyes respectively. These Rh-HoANCs, FITC-ErANCs, and 647-TmANCs were further conjugated with the targeting ligands daidzein, AMD3100, and folic acid respectively. Binding specificities of each nanoprobe to distinct cellular subsets were established by in vitro uptake studies. Quantitative whole-body SWIR imaging of subcutaneous tumor bearing mice was used to validate the in vivo targeting ability of these nanoprobes. Results: Each of the three ligand-functionalized nanoprobes showed significantly higher uptake in the targeted cell line compared to untargeted probes. Increased accumulation of tumor-specific nanoprobes was also measured relative to untargeted probes in subcutaneous tumor models of breast (4175 and MCF-7) and ovarian cancer (SKOV3). Preferential accumulation of tumor-specific nanoprobes was also observed in tumors overexpressing targeted biomarkers in mice bearing molecularly-distinct bilateral subcutaneous tumors, as evidenced by significantly higher signal intensities on SWIR imaging. Conclusions: The results from this study show that tumors can be detected in vivo using a set of targeted multispectral SWIR-emitting nanoprobes. Significantly, these nanoprobes enabled imaging of biomarkers in mice bearing bilateral tumors with distinct molecular phenotypes. The findings from this study provide a foundation for optical molecular imaging of heterogeneous tumors and for studying the response of these complex lesions to targeted therapy.

Naked-eye Visualization of Lymph Nodes Using Fluorescence Nanoprobes in Non-Human Primate-Animal Models

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Aggregation-induced emission luminogens for image-guided surgery in non-human primates

Sentinel lymph node identification using NIR-II ultrabright Raman nanotags on preclinical models

In Vivo Photoacoustic Sentinel Lymph Node Imaging Using Clinically-Approved Carbon Nanoparticles

NIR-II Fluorescence Lymphatic Imaging and Intraoperative Navigation Based on the “isolated Cage” Monodisperse Strategy

Nanoprobes‐Assisted Multichannel NIR‐II Fluorescence Imaging‐Guided Resection and Photothermal Ablation of Lymph Nodes

In Vivo Real-Time Near-Infrared Fluorescent Mapping of Sentinel Lymph Nodes Using Methylene Blue Encapsulated in A Microemulsion Nanosystem

NIR-II and visible fluorescence hybrid imaging-guided surgery via aggregation-induced emission fluorophores cocktails

Near-infrared-II ratiometric fluorescence probes for non-invasive detection and precise navigation surgery of metastatic sentinel lymph nodes

Long-term Multimodal Imaging of Tumor Draining Sentinel Lymph Nodes Using Mesoporous Silica-Based Nanoprobes.

Biocompatible Near-Infrared Fluorescent Nanoparticles for Macro and Microscopic in Vivo Functional Bioimaging.

Rapid and Accurate Detection of Lymph Node Metastases Enabled through Fluorescent Silicon Nanoparticles-Based Exosome Probes

Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo

Intraoperative Surgical Margin Assessment by NIR‐II Imaging with Urine Excretable Nd‐Based Nanoprobe in Breast Cancers

Real-time detection and resection of sentinel lymph node metastasis in breast cancer through a rare earth nanoprobe based NIR-IIb fluorescence imaging

Detection of Lymph Node Metastasis with Near-Infrared Upconversion Luminescent Nanoprobes

CXCR-4 Targeted, Short Wave Infrared (SWIR) Emitting Nanoprobes for Enhanced Deep Tissue Imaging and Micrometastatic Cancer Lesion Detection

Long-Distance Tracing of the Lymphatic System with a Computed Tomography/Fluorescence Dual-Modality Nanoprobe for Surveying Tumor Lymphatic Metastasis.

Aminopeptidase N Activatable Nanoprobe for Tracking Lymphatic Metastasis and Guiding Tumor Resection Surgery via Optoacoustic/NIR-II Fluorescence Dual-Mode Imaging.

Multiplexed NIR-II Probes for Lymph Node-Invaded Cancer Detection and Imaging-Guided Surgery.